Education
About Us
Working with TipRanks
Follow Us
Addex Therapeutics Ltd (ADR) (ADXN)
:ADXN
Top Page
Addex Therapeutics
(NASDAQ:ADXN)
45Neutral
Addex Therapeutics (ADXN) vs. S&P 500 (SPY)
Market Cap
$10.79M
Dividend YieldN/A
Average Volume (3M)8.52K
Price to Earnings (P/E)1.0
Beta (1Y)-0.09
Revenue Growth-70.05%
EPS GrowthN/A
CountryUS
Employees23
SectorHealthcare
Sector Strength74
IndustryBiotechnology
Share Statistics
EPS (TTM)6.82
Shares Outstanding1,536,287
10 Day Avg. Volume10,734
30 Day Avg. Volume8,518
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.25
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Addex Therapeutics Business Overview & Revenue Model
Company DescriptionAddex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
How the Company Makes MoneyAddex Therapeutics generates revenue primarily through strategic partnerships, collaborations, and licensing agreements with larger pharmaceutical companies. These partnerships often involve milestone payments, research funding, and royalties on sales of successfully developed drugs. The company may also benefit from government grants and research support for its scientific endeavors. Its business model relies on advancing its proprietary drug candidates through clinical trials to attract partnerships and potential acquisition interest from larger entities in the pharmaceutical industry.
Addex Therapeutics Financial Statement Overview
Summary
Addex Therapeutics is facing significant financial challenges, including declining revenues, negative profitability, and cash flow issues. Despite a low debt-to-equity ratio, the company relies heavily on financing activities to maintain operations, highlighting the need for strategic improvements in revenue growth and operational efficiencies.Income Statement
Addex Therapeutics has experienced declining revenues with negative growth over the years. The company shows negative gross profit margins, indicating high costs relative to revenues. Net profit margin is also negative, reflecting ongoing profitability challenges. EBIT and EBITDA margins are unfavorable, highlighting operational inefficiencies.30
Negative
Balance Sheet
The balance sheet reveals a low debt-to-equity ratio, indicating minimal leverage, which is positive. However, the company has consistently reported negative net income, leading to poor return on equity. The equity ratio remains strong, suggesting a solid asset base relative to liabilities.40
Negative
Cash Flow
Cash flow analysis shows negative free cash flow, which is concerning for liquidity. The operating cash flow to net income ratio is negative, indicating operational cash flow challenges. Financing activities have been required to support cash flow needs, pointing to reliance on external funding.35
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 557.48K | 1.61M | 1.42M | 2.92M | 3.61M | 2.76M | Gross Profit |
| -988.78K | -5.32M | -13.20M | -9.90M | -6.76M | 2.53M | EBIT |
| -4.99M | -10.28M | -20.52M | -15.51M | -12.24M | -14.83M | EBITDA |
| -6.37M | -10.23M | -20.23M | -14.94M | -12.41M | -14.32M | Net Income Common Stockholders |
| 5.40M | -10.56M | -20.80M | -15.35M | -12.86M | -14.78M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 15.26M | 3.87M | 6.96M | 20.50M | 18.76M | 31.55M | Total Assets |
| 21.74M | 4.64M | 8.28M | 22.54M | 20.18M | 33.03M | Total Debt |
| 0.00 | 344.34K | 373.13K | 482.01K | 567.40K | 550.25K | Net Debt |
| -15.26M | -3.52M | -6.58M | -20.00M | -18.13M | -30.99M | Total Liabilities |
| 5.44M | 3.50M | 3.37M | 5.61M | 5.57M | 7.50M | Stockholders Equity |
| 16.29M | 1.15M | 4.91M | 16.93M | 14.61M | 25.52M |
| Cash Flow | Free Cash Flow | ||||
| -5.97M | -8.00M | -16.44M | -14.74M | -12.24M | -9.51M | Operating Cash Flow |
| -5.97M | -7.99M | -16.44M | -14.71M | -12.18M | -9.48M | Investing Cash Flow |
| 4.66M | -6.84K | 2.97K | -30.31K | -59.41K | -43.25K | Financing Cash Flow |
| 47.02K | 5.26M | 3.10M | 16.40M | 46.40K | -463.69K |
Addex Therapeutics Technical Analysis
Negative
5.34
Price Trends
7.57
Negative
7.73
Negative
8.51
Negative
Market Momentum
-0.05
Positive
43.43
Neutral
35.48
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ADXN, the sentiment is Negative. The current price of 5.34 is below the 20-day moving average (MA) of 7.40, below the 50-day MA of 7.57, and below the 200-day MA of 8.51, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 43.43 is Neutral, neither overbought nor oversold. The STOCH value of 35.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ADXN.
Addex Therapeutics Risk Analysis
Addex Therapeutics disclosed 51 risk factors in its most recent earnings report. Addex Therapeutics reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Addex Therapeutics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $11.40B | 25.61 | 8.05% | ― | 17.35% | 151.40% | |
76 Outperform | $2.50B | 11.00 | 38.89% | ― | 31.85% | ― | |
68 Neutral | $9.50B | 28.95 | 14.16% | ― | 24.81% | 33.67% | |
64 Neutral | $123.99B | ― | -3.15% | ― | 11.64% | -114.72% | |
48 Neutral | $6.36B | 1.28 | -45.04% | 2.64% | 19.24% | 1.69% | |
46 Neutral | $96.00M | ― | -69.10% | ― | -9.55% | 24.57% | |
45 Neutral | $10.79M | 1.01 | -85.36% | ― | -70.05% | ― |
* Healthcare Sector Average
Performance Comparison
ADXN
Addex Therapeutics
6.87
-19.28
-73.73%
ACAD
ACADIA Pharmaceuticals
14.11
-3.30
-18.95%
BMRN
BioMarin Pharmaceutical
56.32
-35.14
-38.42%
NBIX
Neurocrine
90.72
-45.21
-33.26%
VRTX
Vertex Pharmaceuticals
475.49
75.26
18.80%
ENTA
Enanta Pharmaceuticals
4.26
-12.49
-74.57%
Addex Therapeutics Earnings Call Summary
Earnings Call Date: Nov 22, 2024 | % Change Since: -34.16% | Next Earnings Date: Apr 21, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted significant progress in R&D programs, particularly with the GABAB PAM program and Neurosterix advancements, while also pointing out decreased revenue and potential financial risks related to Neurosterix. Despite some financial challenges, the strategic progress and strong cash position provide a positive outlook.Highlights
Progress in GABAB PAM Program
Addex Therapeutics made excellent progress in their GABAB positive allosteric modulator program with the completion of the R&D phase and the selection of a compound for development in substance use disorder by their partner, Indivior. IND-enabling studies have started.
Neurosterix Advancements
The spin-out company, Neurosterix, has made excellent progress, starting IND-enabling studies with its M4 PAM program.
Strong Financial Position
Addex Therapeutics is in a solid position with a strong balance sheet, holding CHF 3.3 million in cash and other assets, providing a solid foundation to deliver on strategic objectives.
Lowlights
Decreased Revenue and R&D Expenses
Revenue decreased to CHF 0.1 million in Q3 2024 compared to CHF 0.3 million in Q3 2023, and R&D expenses decreased by CHF 0.3 million due to the completion of the research phase.
Share of Net Loss in Associates
Addex reported a share of net loss of CHF 0.9 million related to their investment in Neurosterix Group, impacting their financial results.
Potential Dilution Risk
There is a potential risk of dilution for Addex in Neurosterix if additional capital is raised and Addex chooses not to participate.
Company Guidance
During the third quarter 2024 earnings call for Addex Therapeutics, the company provided detailed guidance on their ongoing and future projects. The GABAB positive allosteric modulator (PAM) program, in collaboration with Indivior, is progressing with the initiation of IND-enabling studies for a compound targeting substance use disorders. Addex could achieve up to USD 330 million in regulatory, clinical, and commercial milestones from this partnership, along with tiered royalties from net sales. Additionally, Addex is advancing its independent GABAB PAM program to treat chronic cough, with plans to begin IND-enabling studies in 2025. Financially, Addex reported CHF 0.1 million in income from continuing operations for Q3 2024, with CHF 3.3 million in cash reserves. The company is actively working on repositioning dipraglurant for brain injury recovery and continues its collaboration with Neurosterix, which has started IND-enabling studies for its M4 PAM program.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.